08 - Instant insights: Metabolic Risk Panel (5 min)

Increased rates of obesity and type 2 diabetes are increasing rates of cardiometabolic conditions. Identifying and intervening in early stages of metabolic dysfunction is crucial in order to delay and prevent disease progression. The Metabolic Risk Panel is a comprehensive test that helps identify individuals at risk for metabolic dysfunction, insulin resistance, and cardiovascular disease. The panel includes Hemoglobin A1C, Insulin Resistance Panel with Score, Lipid Panel, and Apolipoprotein B (apoB), which together provide a more detailed picture of cardiometabolic health than traditional tests alone. By incorporating these biomarkers, clinicians can detect metabolic risks earlier, enabling proactive interventions to prevent conditions like Type 2 Diabetes, Cardiovascular Disease, and other related cardiometabolic conditions.   This episode will Outline the components of the Metabolic Risk Panel, including Hemoglobin A1C, insulin resistance panel with score, lipid panel, and Apolipoprotein B, and how they improve risk assessment. (0:33) Explain the role of insulin resistance in the development of metabolic dysfunction and its connection to early signs of type 2 diabetes. (2:25) Recognize the importance of apolipoprotein B (apoB) in evaluating lipid metabolism and its role in cardiovascular risk assessment, especially in patients with insulin resistance or metabolic syndrome. (3:15) Identify how combining traditional and advanced biomarkers in the Metabolic Risk Panel helps clinicians catch metabolic and cardiovascular risks early, enabling more effective prevention and management. (4:30) The content was current as of the time of recording. To learn more, please review the additional resources below for information on our cardiovascular, metabolic, endocrine, and wellness offerings as well as educational resources and insights from our team of experts. At Quest Diagnostics, we are committed to providing you with results and insights to support your clinical decisions.  Date: 12/2024 Speaker(s): Maeson Latsko, PhD Contributor(s): Maeson Latsko, PhD; Trisha Winchester, PhD Additional Resources: Quest Diagnostics Clinical Education Center [Link] Ordering information: Metabolic Risk Panel [link] References:   Cannon A, Handelsman Y, Heile M, Shannon M. Burden of illness in type 2 diabetes mellitus. J Manag Care Spec Pharm. 2018;24(9-a Suppl):S5-S13. doi:10.18553/jmcp.2018.24.9-a.s5 Johannesen CDL, Langsted A, Nordestgaard BG, Mortensen MB. Excess apolipoprotein B and cardiovascular risk in women and men. J Am Coll Cardiol. 2024;83(23):2262-2273. doi:10.1016/j.jacc.2024.03.423   Centers of Medicare & Medicaid Services. Diabetes Screening & Definitions Update: CY 2024 physician fee schedule final rule. June 25, 2024. Accessed December 19, 2024. https://www.cms.gov/files/document/mm13487-diabetes-screening-definitions-update-cy-2024-physician-fee-schedule-final-rule.pdf   Centers for Disease Control and Prevention. (2017). National diabetes statistics report, 2017: Estimates of Diabetes and its Burden in the United States. Retrieved from https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf